GenFleet Therapeutics (Shanghai) Inc. (2595) Announces Breakthrough Therapy Designation for KRAS G12D Inhibitor in China

Bulletin Express03-02

GenFleet Therapeutics (Shanghai) Inc. (GenFleet, 2595) reported that its oral KRAS G12D (ON/OFF) inhibitor GFH375 received Breakthrough Therapy Designation from the Center for Drug Evaluation of the National Medical Products Administration. This designation applies to KRAS G12D-mutant non-small cell lung cancer in patients who have received at least one prior systemic therapy.

According to phase I/II data from the GFH375X1101 study, GFH375 as a monotherapy has demonstrated encouraging efficacy and a manageable safety profile in the global KRAS G12D inhibitor landscape. Results from this study have been presented at major academic conferences, including the American Society of Clinical Oncology Annual Meeting and the World Conference on Lung Cancer, with further data releases anticipated later in the year.

GenFleet’s research and development efforts for GFH375 include its advancement into the world’s first phase III trial of an oral KRAS G12D inhibitor in metastatic pancreatic cancer. GFH375 has also been granted Fast Track Designation by the U.S. FDA for metastatic KRAS G12D-mutated pancreatic ductal adenocarcinoma, and multiple combination and monotherapy trials are underway in various tumor types.

GFH375 stems from a discovery and development partnership between GenFleet and Verastem Oncology. GenFleet holds rights to GFH375 within China, while Verastem Oncology holds rights outside China. The latest announcement highlights the significant potential of GFH375 for treating KRAS G12D-driven cancers and indicates plans for continued data updates at global academic events later this year.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1148484961?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-02 09:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1148484961","market":"us","top_or_hot":-1,"title":"GenFleet Therapeutics (Shanghai) Inc. (2595) Announces Breakthrough Therapy Designation for KRAS G12D Inhibitor in China","media":"Bulletin Express","content":"<p>GenFleet Therapeutics (Shanghai) Inc. (GenFleet, 2595) reported that its oral KRAS G12D (ON/OFF) inhibitor GFH375 received Breakthrough Therapy Designation from the Center for Drug Evaluation of the National Medical Products Administration. This designation applies to KRAS G12D-mutant non-small cell lung cancer in patients who have received at least one prior systemic therapy.</p>\n<p>According to phase I/II data from the GFH375X1101 study, GFH375 as a monotherapy has demonstrated encouraging efficacy and a manageable safety profile in the global KRAS G12D inhibitor landscape. Results from this study have been presented at major academic conferences, including the American Society of Clinical Oncology Annual Meeting and the World Conference on Lung Cancer, with further data releases anticipated later in the year.</p>\n<p>GenFleet’s research and development efforts for GFH375 include its advancement into the world’s first phase III trial of an oral KRAS G12D inhibitor in metastatic pancreatic cancer. GFH375 has also been granted Fast Track Designation by the U.S. FDA for metastatic KRAS G12D-mutated pancreatic ductal adenocarcinoma, and multiple combination and monotherapy trials are underway in various tumor types.</p>\n<p>GFH375 stems from a discovery and development partnership between GenFleet and Verastem Oncology. GenFleet holds rights to GFH375 within China, while Verastem Oncology holds rights outside China. The latest announcement highlights the significant potential of GFH375 for treating KRAS G12D-driven cancers and indicates plans for continued data updates at global academic events later this year.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>GenFleet Therapeutics (Shanghai) Inc. (2595) Announces Breakthrough Therapy Designation for KRAS G12D Inhibitor in China</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGenFleet Therapeutics (Shanghai) Inc. (2595) Announces Breakthrough Therapy Designation for KRAS G12D Inhibitor in China\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-03-02 09:21</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>GenFleet Therapeutics (Shanghai) Inc. (GenFleet, 2595) reported that its oral KRAS G12D (ON/OFF) inhibitor GFH375 received Breakthrough Therapy Designation from the Center for Drug Evaluation of the National Medical Products Administration. This designation applies to KRAS G12D-mutant non-small cell lung cancer in patients who have received at least one prior systemic therapy.</p>\n<p>According to phase I/II data from the GFH375X1101 study, GFH375 as a monotherapy has demonstrated encouraging efficacy and a manageable safety profile in the global KRAS G12D inhibitor landscape. Results from this study have been presented at major academic conferences, including the American Society of Clinical Oncology Annual Meeting and the World Conference on Lung Cancer, with further data releases anticipated later in the year.</p>\n<p>GenFleet’s research and development efforts for GFH375 include its advancement into the world’s first phase III trial of an oral KRAS G12D inhibitor in metastatic pancreatic cancer. GFH375 has also been granted Fast Track Designation by the U.S. FDA for metastatic KRAS G12D-mutated pancreatic ductal adenocarcinoma, and multiple combination and monotherapy trials are underway in various tumor types.</p>\n<p>GFH375 stems from a discovery and development partnership between GenFleet and Verastem Oncology. GenFleet holds rights to GFH375 within China, while Verastem Oncology holds rights outside China. The latest announcement highlights the significant potential of GFH375 for treating KRAS G12D-driven cancers and indicates plans for continued data updates at global academic events later this year.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02595","symbol_name":"劲方医药-B","start_time":0,"source_url":"","article_id":"1148484961","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1148484961","pubTimestamp":1772414516,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"GenFleet Therapeutics (Shanghai) Inc. (GenFleet, 2595) reported that its oral KRAS G12D (ON/OFF) inhibitor GFH375 received Breakthrough Therapy Designation from the Center for Drug Evaluation of the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02595":"劲方医药-B"},"translate_title":"GenFleet Therapeutics(Shanghai)Inc.(2595)宣布KRAS G12D抑制剂在中国获得突破性疗法认定","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02595":1},"content_text":"GenFleet Therapeutics (Shanghai) Inc. (GenFleet, 2595) reported that its oral KRAS G12D (ON/OFF) inhibitor GFH375 received Breakthrough Therapy Designation from the Center for Drug Evaluation of the National Medical Products Administration. This designation applies to KRAS G12D-mutant non-small cell lung cancer in patients who have received at least one prior systemic therapy.\nAccording to phase I/II data from the GFH375X1101 study, GFH375 as a monotherapy has demonstrated encouraging efficacy and a manageable safety profile in the global KRAS G12D inhibitor landscape. Results from this study have been presented at major academic conferences, including the American Society of Clinical Oncology Annual Meeting and the World Conference on Lung Cancer, with further data releases anticipated later in the year.\nGenFleet’s research and development efforts for GFH375 include its advancement into the world’s first phase III trial of an oral KRAS G12D inhibitor in metastatic pancreatic cancer. GFH375 has also been granted Fast Track Designation by the U.S. FDA for metastatic KRAS G12D-mutated pancreatic ductal adenocarcinoma, and multiple combination and monotherapy trials are underway in various tumor types.\nGFH375 stems from a discovery and development partnership between GenFleet and Verastem Oncology. GenFleet holds rights to GFH375 within China, while Verastem Oncology holds rights outside China. The latest announcement highlights the significant potential of GFH375 for treating KRAS G12D-driven cancers and indicates plans for continued data updates at global academic events later this year.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease,SGX","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1148484961","isCrawlerRequest":true}